ACADIA (ACAD) Q4 FY25 earnings call

ACADIA Pharmaceuticals closed FY25 with strong commercial execution for both NUPLAZID and DAYBUE, exceeding $1 billion in annual adjusted revenues for the first time. The company is making foundational SG&A investments to support continued growth towards 2028 targets, while navigating higher-than-anticipated IRA rebates and a negative EU regulatory trend vote for DAYBUE. The R&D pipeline is advancing, with a key Phase II readout for remlifanserin expected later in 2026.